Update of adjuvant chemotherapy for resected gastric cancer

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Gastric cancer is the second cause of cancer that is related to death and the fourth most common cancer, worldwide. Complete resection of cancer is the only curative treatment for gastric cancer. However, even if complete resection is possible, recurrence is frequently observed in Gastric patients. Therefore, adjuvant treatment modality for resectable gastric cancer is needed to increase the survival of patients. This study wants to describe the role of adjuvant chemotherapy for resectable gastric cancer, with updated data of recent studies. Several meta-analysis studies demonstrated a benefit of adjuvant chemotherapy for resectable gastric cancer. Due to the heterogeneity of the population and regimens, there is no consensus regarding the adjuvant chemotherapy. Recently published, well designed phase III studies demonstrated the statistically significance of adjuvant chemotherapy for the resectable gastric cancer, with the extended lymph node dissection. Further phase III trials, to determine the best regimen and schedule of adjuvant chemotherapy, was suggested to use the fluoropyrimidine based regimen as control group.

Original languageEnglish
Pages (from-to)3-6
Number of pages4
JournalJournal of Gastric Cancer
Volume12
Issue number1
DOIs
Publication statusPublished - 2012 Oct 22

Fingerprint

Adjuvant Chemotherapy
Stomach Neoplasms
Second Primary Neoplasms
Population Characteristics
Lymph Node Excision
Meta-Analysis
Neoplasms
Stomach
Appointments and Schedules
Recurrence
Control Groups
Survival
Therapeutics

Keywords

  • Adjuvant chemotherapy
  • Gastric cancer
  • Review

ASJC Scopus subject areas

  • Gastroenterology
  • Oncology
  • Cancer Research

Cite this

Update of adjuvant chemotherapy for resected gastric cancer. / Oh, Sang Cheul.

In: Journal of Gastric Cancer, Vol. 12, No. 1, 22.10.2012, p. 3-6.

Research output: Contribution to journalArticle

@article{2ea8cf27788a401da6195f841b57d6c3,
title = "Update of adjuvant chemotherapy for resected gastric cancer",
abstract = "Gastric cancer is the second cause of cancer that is related to death and the fourth most common cancer, worldwide. Complete resection of cancer is the only curative treatment for gastric cancer. However, even if complete resection is possible, recurrence is frequently observed in Gastric patients. Therefore, adjuvant treatment modality for resectable gastric cancer is needed to increase the survival of patients. This study wants to describe the role of adjuvant chemotherapy for resectable gastric cancer, with updated data of recent studies. Several meta-analysis studies demonstrated a benefit of adjuvant chemotherapy for resectable gastric cancer. Due to the heterogeneity of the population and regimens, there is no consensus regarding the adjuvant chemotherapy. Recently published, well designed phase III studies demonstrated the statistically significance of adjuvant chemotherapy for the resectable gastric cancer, with the extended lymph node dissection. Further phase III trials, to determine the best regimen and schedule of adjuvant chemotherapy, was suggested to use the fluoropyrimidine based regimen as control group.",
keywords = "Adjuvant chemotherapy, Gastric cancer, Review",
author = "Oh, {Sang Cheul}",
year = "2012",
month = "10",
day = "22",
doi = "10.5230/jgc.2012.12.1.3",
language = "English",
volume = "12",
pages = "3--6",
journal = "Journal of Gastric Cancer",
issn = "2093-582X",
publisher = "Korean Gastric Cancer Association",
number = "1",

}

TY - JOUR

T1 - Update of adjuvant chemotherapy for resected gastric cancer

AU - Oh, Sang Cheul

PY - 2012/10/22

Y1 - 2012/10/22

N2 - Gastric cancer is the second cause of cancer that is related to death and the fourth most common cancer, worldwide. Complete resection of cancer is the only curative treatment for gastric cancer. However, even if complete resection is possible, recurrence is frequently observed in Gastric patients. Therefore, adjuvant treatment modality for resectable gastric cancer is needed to increase the survival of patients. This study wants to describe the role of adjuvant chemotherapy for resectable gastric cancer, with updated data of recent studies. Several meta-analysis studies demonstrated a benefit of adjuvant chemotherapy for resectable gastric cancer. Due to the heterogeneity of the population and regimens, there is no consensus regarding the adjuvant chemotherapy. Recently published, well designed phase III studies demonstrated the statistically significance of adjuvant chemotherapy for the resectable gastric cancer, with the extended lymph node dissection. Further phase III trials, to determine the best regimen and schedule of adjuvant chemotherapy, was suggested to use the fluoropyrimidine based regimen as control group.

AB - Gastric cancer is the second cause of cancer that is related to death and the fourth most common cancer, worldwide. Complete resection of cancer is the only curative treatment for gastric cancer. However, even if complete resection is possible, recurrence is frequently observed in Gastric patients. Therefore, adjuvant treatment modality for resectable gastric cancer is needed to increase the survival of patients. This study wants to describe the role of adjuvant chemotherapy for resectable gastric cancer, with updated data of recent studies. Several meta-analysis studies demonstrated a benefit of adjuvant chemotherapy for resectable gastric cancer. Due to the heterogeneity of the population and regimens, there is no consensus regarding the adjuvant chemotherapy. Recently published, well designed phase III studies demonstrated the statistically significance of adjuvant chemotherapy for the resectable gastric cancer, with the extended lymph node dissection. Further phase III trials, to determine the best regimen and schedule of adjuvant chemotherapy, was suggested to use the fluoropyrimidine based regimen as control group.

KW - Adjuvant chemotherapy

KW - Gastric cancer

KW - Review

UR - http://www.scopus.com/inward/record.url?scp=84867526768&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84867526768&partnerID=8YFLogxK

U2 - 10.5230/jgc.2012.12.1.3

DO - 10.5230/jgc.2012.12.1.3

M3 - Article

C2 - 22500257

AN - SCOPUS:84867526768

VL - 12

SP - 3

EP - 6

JO - Journal of Gastric Cancer

JF - Journal of Gastric Cancer

SN - 2093-582X

IS - 1

ER -